Results. Overall, we found no difference in hemoglobin-normalized newborn 12 folate concentrations (HbFol, nmol/g) between ALL cases and controls (2.76 vs. 13 2.77, p=0.97) or between AML cases and controls (2.93 vs. 2.76, p=0.32). Null 14 results persisted after stratification by both birth period (1982-94, 1995-98, and 15 1999-2002) to account for the start of folate fortification of grain products in the 16 US, and by self-reported maternal pre-pregnancy supplement use. Similarly, no 17 association was observed for major ALL subgroups. 18
Introduction

2
Leukemia is the most common cancer among children under 15 years of age, 3 comprising 31% of all childhood cancers diagnosed in the U.S. (1) . The etiology 4 of childhood leukemia, however, is poorly understood. Due to the disease's early 5 age of onset, prenatal and early life exposures are thought to play a major role in 6 leukemogenesis. 7
Folate is an important micronutrient involved in both maintenance of DNA 8 replication fidelity and provision of methyl groups for epigenetic control of DNA 9 expression. Recent epidemiologic studies have examined the role of folate in the 10 etiology of childhood acute lymphoblastic leukemia (ALL), the most common form 11 of childhood leukemia (2-4). Some studies of genetic susceptibility to ALL provide 12 evidence of association for folate pathway genes in both the child (5) and the 13 mother (6). However, no associations were reported for risk of ALL in both a 14 recent meta-analysis of folate supplementation during pregnancy (4) and our 15 previous study of pre-pregnancy maternal dietary folate intake (2), although there 16 does appear to be limited evidence of an inverse association between risk of ALL 17 and maternal folate supplementation prior to pregnancy (4) . No studies have 18 reported on the potential association of folate with childhood acute myeloid 19 leukemia (AML), which accounts for 15% of childhood leukemia cases. 20
21
The folate measures used in previous epidemiologic studies are indirect or 22 incomplete measures of the folate exposure experienced by the developing fetus. 23
Exposure of the fetus is influenced by (a) the mother's intake from both dietary 24 sources and supplements, (b) the mother's folate transport and metabolism 25 capacity, and (c) the fetus's own transport and metabolism capacity. It is possible 26 that elucidating the etiologic role of folate in childhood ALL risk will require that 27 these factors be accounted for concomitantly. This has not been done in the 28 previous epidemiologic studies that have examined dietary factors and genes, 29
and may have contributed to the current lack of clarity in the literature. 30
Additionally, mandatory fortification of flour and grains over the last two decades 1 in the US (7) and elsewhere may have complicated efforts to study the potential 2 effects of folate intake and/or supplementation on childhood leukemia risk. 3
4
To better address these concerns and directly assess the role of folate in 5 childhood leukemia, we conducted a population-based case-control study in 6
California examining levels of folate at birth in neonatal dried blood spot (DBS) 7 specimens. 8
Materials and Methods
9
Study subjects and specimens
10
Cases of childhood ALL and AML were participants in the Northern California 11
Childhood Leukemia Study (NCCLS), a previously described population-based 12 case-control study (2, 8 
DBS folate assays
24
For each subject, a sample of a DBS specimen, corresponding to approximately 25 10-12 µl of whole blood, was extracted for folate analysis by the Lactobacillus 26 casei microbiologic growth assay (11). Hemoglobin (Hb) concentration was 27 measured in the same DBS extract using a sodium lauryl sulfate assay (12), and 28 results were used to calculate HbFol (folate levels normalized to Hb, nmol/g), 29
which is independent of the blood volume or blood dilution in the DBS. This in DBS were on average 6% lower than in whole blood) were obtained (14). The 11 DBS folate assay work was all conducted in the same lab by staff masked to 12 case-control status. To ensure the quality of folate and Hb measurements, three 13 quality control (QC) pools of whole blood folate (8.6-11.6% inter-assay CV) and 14 Hb (3.4-3.9% inter-assay CV) were analyzed in duplicate with each batch. To 15 ensure the quality of the DBS extraction, two DBS QC pools were analyzed in 16 duplicate with each batch (9.5-10.5% inter-assay CV). HbFol results for subject 17 samples were only reported when all three sets of bench QC passed the 18
predefined QC rules (15). 19
Statistical analysis 20
We compared means of log-transformed neonatal HbFol concentrations in cases 21 with those in controls after adjusting for age, gender, race/ethnicity, year of birth, 22 and income. We used analysis of variance methods as implemented in PROC 23 GLM in SAS 9.2, estimating adjusted means using the LSMEANS statement and 24 testing for significance of differences between cases and controls using T-tests. 25
Presented means and standard errors were back-transformed to HbFol. For ALL, 26 we also calculated means by major subgroups defined previously (16) , including 27 total B-cell ALL, B-cell ALL with high hyperdiploidy (>51 chromosomes), and total 28 T-cell ALL. In addition, because of the low prevalence of most individual 29 structural abnormalities (translocations, inversions, and deletions), we examined 30 the broad category of B-cell ALL with "any structural abnormalities", as structural abnormalities overall may be due to decreased fidelity of DNA replication. Mixed 1 lineage leukemias (N=4) were excluded from subgroup analysis due to their rarity. 2
To account for potential differences due to status of folate fortification programs 3 in place at birth, we stratified by birth year: 1982-1994 (pre-fortification), 1995-4 1998 (fortification transition), and 1999-2002 (post-fortification). For similar 5 reasons, we also stratified by maternal pre-pregnancy supplement use (yes/no). 6
Results
8
Characteristics of the 313 ALL cases, 44 AML cases, and 405 controls are 9 presented in Table 1 . As expected due to the matched design, cases and 10 controls were comparable in terms of age, gender, and ethnicity. Control 11 households tended to have higher income, a covariate that was adjusted for in 12 the statistical analysis. 
number of T-cell ALL cases vs. controls in our study population (3.
In this study, we aimed to assess whether a child's folate concentration in 9 neonatal DBS specimens, which we postulated was reflective of both the child's 10 folate exposure at the end of pregnancy (via maternal diet, supplementation, and 11 other factors) and the child's own folate metabolism, was associated with risk of 12 childhood leukemia. We found no association of folate concentrations at birth 13 with either total ALL or total AML. No significant differences in HbFol 14 concentrations were observed between the controls and any of the major ALL 15 subgroups, including total B-cell ALL, B-cell high hyperdiploid ALL, or B-cell ALL 16 with structural abnormalities. Thus, our results indicate that folate concentrations 17 at birth are not associated with childhood AML or major ALL subgroups. In the 18 relatively small subgroup of T-cell ALL cases, however, we observed significantly 19 higher folate levels than among controls. This provocative observation will need 20 to be replicated in future studies with larger sample sizes. of our study indicate that folate levels at birth are not associated with risk of 1 subsequent childhood leukemia (with the possible exception of T-cell ALL), they 2 do not rule out a role for maternal dietary folate or folate supplementation before 3 or during early pregnancy (pre-conception or peri-conception), or potentially after 4
birth. 5 6
When we converted HbFol to RBC folate concentrations using the MCHC, we 7 found that all children but one (245 nmol/L) had RBC folate concentrations above 8 the WHO recommended low folate threshold of 340 nmol/L, regardless whether 9 the DBS samples were collected pre-or post-fortification (18) . In contrast, 10 prevalence estimates of low RBC folate among US adults during pre-fortification 11 ranged from 2.1-4.5%, while post-fortification they were <1% (19). Indeed, it has 12 been well established that newborns generally have high folate status (20), with 13 transport of folate across the placenta being established early in pregnancy (21). 14 15
The meaning of our observation that T-cell ALL cases have slightly higher folate 16 concentrations at birth than comparable controls is unclear. Although early high 17 folate is typically viewed as a factor associated with either a reduced or null risk 18 of various diseases, folate is also a possible promoter after cancer initiation due 19 to the fast-growing cancer cell's need for folate (22), a fact that has been 20 exploited with chemotherapeutic success for childhood leukemia and other 21 cancers in the form of the folate poison methotrexate (23). 22
23
In our study, among cases and controls combined, we observed significant 24 correlations of neonatal folate levels with the following surrogate folate 25 measures: total maternal folate intake (supplements + food sources, Spearman 26 correlation coefficient = 0.086, p=0.017) and maternal supplemental folic acid 27 alone (Spearman correlation coefficient = 0.153, p<0.0001). Additionally, we 28 observed that HbFol mean concentrations tended to be higher among children 29 whose mothers reported using pre-pregnancy supplements than among those 30 whose mothers did not, an effect that was true for all birth periods. These observations provide reassurance that the HbFol concentrations measured in 1 neonatal blood are indeed affected by self-reported maternal intake and 2 supplementation, and that these surrogate measures have some validity. That 3 the correlation coefficients were very weak, however, suggests that other factors, 4 including maternal genes, child's genes, and other perhaps unmeasured factors 5 modulate neonatal folate concentrations. This is an area for future study. 6 7 This study has several unique strengths. The microbiologic folate assay method 8 used in our study is accurate; indeed the accuracy of other folate assay methods 9 is evaluated against the microbiologic assay (24, 25). While the DBS assay has 10 higher imprecision than the whole blood assay, it allows the use of neonatal DBS 11 specimens, which to our knowledge, no other studies to date have done. This is 12 important because of the timing of collection of these specimens: the levels of 13 folate reported here represent the folate status of the child at the end of 14 pregnancy, a more direct measure of the child's pre-diagnostic folate exposure 15 than other surrogate measures used previously, such as maternal folate 16 supplementation before or during pregnancy. In addition, the matched case-17 control design mitigates concerns regarding potential confounding by racial or 18 ethnic differences, particularly as childhood ALL incidence rates are higher in 19
Hispanics than non-Hispanics in California (26). 20
21
We acknowledge that by comparing each subtype of cases to the same control 22 group, we have conducted non-independent statistical tests, which might 23 increase the risk of false positive associations. Nonetheless, the observations 24 were null except for a significant finding for T-cell ALL at a relatively robust 25 p=0.003. This finding is based on a relatively small sample size (n=27 cases), 26 however, and may be due to chance. Our null findings for total AML and ALL and 27 for major ALL subgroups, including total B-cell ALL, B-cell ALL with structural 28 changes, and B-cell high hyperdiploid ALL, are robust. It is possible that a study 29 that includes much larger numbers of the subtypes might observe significant 30 differences; however, the adjusted mean estimates were not markedly different 31 from one another. In addition, the low prevalence of folate insufficiency (RBC 1 folate <340 nmol/L) may have precluded observation of putative effects 2 attributable to extremely low folate levels. 3 4
In conclusion, in this case-control study using a biomarker of folate status, we 5 found that folate concentrations at birth were not significantly associated with 6 childhood AML or major subgroups of childhood ALL. These null findings, taken 7 with our observation that newborns do not have low folate status at birth, suggest 8 that any role played by folate in childhood leukemia risk is likely to occur either 9 very early in the pregnancy while the child is in utero (i.e., the peri-conceptional 10 period), or during the post-natal period resulting from the child's own exposures 11 after birth. Future studies should characterize the influence of maternal and child 12 factors, including genetic factors, on neonatal folate levels, and examine the 13 effects of post-natal exposures to folate on childhood leukemia risk. 
